TIVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tivic Health Systems Inc (TIVC) is not a strong buy at the moment for a beginner investor with a long-term focus. The company's financials show improvement in revenue and net income, but the significant losses, negative gross margin, and lack of clear trading signals or positive sentiment make it a risky investment. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on buying this stock until clearer positive catalysts or stronger financial performance emerge.
The technical indicators are neutral. The MACD is slightly positive but contracting, RSI is neutral at 51.657, and moving averages are converging. The stock is trading near its support level (S1: 0.877) with a pre-market price of 0.9603, down 2.88%. There is no strong bullish or bearish signal currently.
Tivic Health has improved its cash position to $12.6 million and identified a $20 billion oncology market opportunity. The company has also transitioned into an immunotherapy company with a focus on the TLR5 platform and completed an in-house manufacturing acquisition.
Gross margin is significantly negative (-99.32%), and EPS has dropped by 49.87% YoY. There are no significant hedge fund or insider trading trends, and the stock has a 90% chance of declining slightly (-0.48%) in the next day.
In Q3 2025, revenue increased by 15.87% YoY to $146,000, and net income improved by 81.41% YoY to -$2,596,000. However, gross margin dropped significantly to -99.32%, and EPS declined by 49.87% YoY to -1.97.
No analyst rating data or price target changes are available for TIVC.
